553635-34-0

Basic information

• Product Name: (S)-4-(2-chlorophenyl)-1-[4-(2,3-dihydroxypropylamino)-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbonyl]piperidine-4-carbonitrile
• Synonyms: (S)-4-(2-chlorophenyl)-1-[4-(2,3-dihydroxypropylamino)-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbonyl]piperidine-4-carbonitrile
• CAS NO: 553635-34-0
• Molecular Weight: 531.014
• Mol File: 553635-34-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: (S)-4-(2-chlorophenyl)-1-[4-(2,3-dihydroxypropylamino)-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbonyl]piperidine-4-carbonitrile(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-4-(2-chlorophenyl)-1-[4-(2,3-dihydroxypropylamino)-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbonyl]piperidine-4-carbonitrile(553635-34-0)
• EPA Substance Registry System: (S)-4-(2-chlorophenyl)-1-[4-(2,3-dihydroxypropylamino)-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbonyl]piperidine-4-carbonitrile(553635-34-0)

Safety Data

• Hazardous Substances Data: 553635-34-0(Hazardous Substances Data)

Upstream product

• 186347-31-9 4-(2-chlorophenyl)-4-cyanopiperidine-1-carboxylic acid tert-butyl ester 
• 343633-13-6 lithium 7-benzenesulfonyl-4-chloro-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylate 
• 186347-33-1 4-(2-chlorophenyl)-piperidine-4-carbonitrile hydrochloride 
• 553635-33-9 (S)-1-[7-benzenesulfonyl-4-(2,3-dihydroxypropylamino)-2-phenyl-7H-pyrrolo[2,3-d]pyrimidine-6-carbonyl]-4-(2-chlorophenyl)piperidine-4-carbonitrile 

Relevant articles and documents

Pyrrolopyrimidine A2b selective antagonist compounds, their synthesis and use

The subject invention provides compounds having the structure: 1 wherein,R1 is a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra;R2 is hydrogen or a substituted or unsubstituted alkyl, wherein the substituent is hydroxyl, dihydroxy, carboxyl, —C(═O)NRaRb, —NRaRb, —NRaC(═O)NRaRb, —NRaC(═O)ORa, —OC(═O)NRaRb, or —NHC(═O)Ra, orR1, R2 and N together form a substituted piperazine, substituted azetidine ring, or a pyrrolidine ring substituted with —(CH2)2OH or —CH2C(═O)OH;R3 is a substituted or unsubstituted phenyl or a 5-6 membered heteroaryl ring, wherein the substituent is halogen, hydroxyl, cyano, (C1-C15)alkyl, (C1-C15)alkoxy, or —NRaRb;R4 is hydrogen or substituted or unsubstituted (C1-C15)alkyl;R5 is —(CH2)mOR6, —CHNOR7, —C(═O)NR8R9, —(CH2)mC(═O)OR10, —(CH2)kC(═O)NR11R12;wherein R6 is a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or 4-8 membered heterocyclic ring;R7 is hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl;R8 and R9 are each independently hydrogen, or a substituted or unsubstituted (C1-C30)alkyl, (C1-C30)alkylaryl, (C1-C30)alkylamino, (C1-C30)alkoxy, or a saturated or unsaturated, monocyclic or bicyclic, carbocyclic or heterocyclic ring, orR8, N, and R9 together form a substituted or unsubstituted 4-8 membered heterocyclic ring;R10 is hydrogen or a substituted or unsubstituted (C1-C30)alkyl, (C3-C10)cycloalkyl, or an aryl, heteroaryl or heterocyclic ring;R11, N and R12 together form a 4-8 membered heterocyclic ring;Ra and Rb are each independently hydrogen or alkyl;m is 0, 1, 2 or 3; andk is 1, 2 or 3,or a specific enantiomer thereof, or a specific tautomer thereof, or a pharmaceutically acceptable salt thereof, and a method for treating a disease associated with the A2b adenosine receptor in a subject in need of such treatment comprising administering to the subject a therapeutically effective amount of the compounds of the invention.